Viral safety control is a key component in the development of gene therapy formulations. Viral contamination may not only lead to reduced therapeutic efficacy but also cause serious safety issues, such as infection, immune response and carcinogenic risk. Therefore, ensuring the viral safety of gene therapy formulations is fundamental to patient safety and product efficacy. CD Formulation has extensive research and service experience in the development of gene therapy formulations, and we have established various state-of-the-art technology platforms to support the development and quality control testing of gene therapy formulations.
Viral safety control is a critical part of the gene therapy product development process. Viral contamination may not only lead to the reduction of therapeutic effect but also cause serious safety problems. Therefore, ensuring the viral safety of gene therapy formulations is the basis for guaranteeing the effectiveness of the products.
Platforms & Technologies | Content Description |
---|---|
Virus testing of cell substrates and raw materials | The cell lines and raw materials used are tested for viral contamination, including screening for endogenous and exogenous viruses, to ensure that they do not contain viruses that may be infectious or pathogenic to humans. |
Assessment of the viral clearance capacity of the production process | Ensure that the final product is free of infectious viral contamination by assessing the viral clearance capacity of the various steps in the production process, including virus filtration, inactivation and purification. |
Virus detection and characterization techniques | Use polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), immunofluorescence, virus neutralization test and other methods to detect and identify viruses in products. |
Virus removal or inactivation validation | Demonstrate that the virus removal steps in the manufacturing process are effective in removing or inactivating viruses through laboratory-scale validation studies using an indicator virus challenge product. |
Viral vector purification process evaluation | Ensure the viral safety of your product by evaluating the ability of the purification process to remove viral vectors for gene therapy formulations that use viral vectors. |
Technology: Virus security evaluation
Journal: Appl Biosaf
Published: 2020
While gene therapy has emerged as a promising option in the treatment of a wide range of diseases, the technique still carries risks. Therefore, there is a need to ensure the effectiveness and safety of gene therapy vectors in gene therapy research. The inventive use of viral vectors and non-viral gene delivery technologies has allowed the science of gene therapy to advance remarkably in recent years. Although these technologies have advanced over the years, no system exists at this time that can be used for gene therapy in vivo or in vitro across all cell types.This paper describes the approach of viral vectors in gene therapy concerning biosafety issues and current approaches in risk assessment, based on problems in the application of viral vectors.
CD Formulation can provide comprehensive and reliable viral safety testing and evaluation services for gene therapy formulations with a professional technical team, advanced testing equipment, customized service solutions, strict quality control system and many other service advantages. If you are interested in us, please feel free to contact us.
References